NK cells: key to success of DC-based cancer vaccines?
/in Dendritic Cells, International Publications /von 2012-08-20 / Oncologist 2012;17(10):1256-70The use of oncolytic viruses to overcome lung cancer drug resistance
/in International Publications, Newcastle Disease Virus /von 2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91Newcastle disease virus: a promising agent for tumour immunotherapy
/in International Publications, Newcastle Disease Virus /von 2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de